Biogen Inc (NASDAQ:BIIB) To Present New MS Data At 32nd ECTRIMS Congress

biogen

Biogen Inc (NASDAQ:BIIB) has announced on Thursday that it will be presenting new data from the Multiple Sclerosis (MS) Cost of Illness (COI) study and updated clinical findings from its extensive MS therapy portfolio at the 32nd European Committee for Treatment and Research in MS (ECTRIMS) Congress, which will last from Wednesday until Saturday.

Story continues below

MS COI Study

The company will present data gathered from over 16,000 multiple sclerosis (MS) patients in Europe as part of the new MS COI study, which originated in 2005. Gisela Kobelt, Ph.D., European Health Economics President and MS COI Study Author, will spearhead the presentation at the event. Moreover, she will also facilitate a workshop, which aims to minimize the burden associated with MS, for patient groups and clinical advisors.

Ralph Kern, M.D., Biogen Senior Vice President (SVP) of Worldwide Medical, said, “We encourage an open discussion about how the community can apply the main findings of the study to engage and educate researchers, governments, and policy makers around the issues most critical to patients, and, ultimately, identify new ways to improve outcomes in the treatment of MS.”

MS Therapy Portfolio Updates

Biogen will also present new findings under its extensive portfolio of MS drugs. The presentations at the 32nd ECTRIMS Congress will highlight updates relating to TECFIDERA (dimethyl fumarate), the leading oral MS treatment around the world; and ZINBRYTA (daclizumab), a new subcutaneous treatment.

These include new clinical evidence establishing the sustained efficacy of TECFIDERA in minimizing the disease activity among relapsing-remitting MS (RRMS) patients; and additional clinical data reiterating its safety among patients who have received up to nine years of prior treatments.

As for ZINBRYTA, Biogen will present new data from the DECIDE clinical trial establishing its positive impact on no evidence of disease activity (NEDA); and interim results from the EXTEND clinical trial establishing the safety and efficacy profile of the drug for up to five years.

Biogen has ended the previous session at $307.73, down 1.46%. During the trading day, the stock has reached a high of $312.45 and a low of $307.42.

An ad to help with our costs